Starling Oncology Institute, Inc. Common Stock
STLN
115 hedge funds and large institutions have $119M invested in Starling Oncology Institute, Inc. Common Stock in 2026 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 51 increasing their positions, 27 reducing their positions, and 26 closing their positions.
1,368% more call options, than puts
Call options by funds: $9.35M | Put options by funds: $637K
89% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 27
0.1% more ownership
Funds ownership: 39.12% → 39.22% (+0.1%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
4% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 26
2% less funds holding
Funds holding: 117 → 115 (-2)
13% less capital invested
Capital invested by funds: $137M → $119M (-$18.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$2.4M |
| 2 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$1.92M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.87M |
| 4 |
BlackRock
New York
|
+$1.57M |
| 5 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
+$1.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CP
CenterBook Partners
Greenwich,
Connecticut
|
-$4.48M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.12M |
| 3 |
MCM
Massar Capital Management
Stamford,
Connecticut
|
-$1.42M |
| 4 |
GC
GatePass Capital
Independence,
Ohio
|
-$1.28M |
| 5 |
FL
FreeGulliver LLC
New Orleans,
Louisiana
|
-$1.27M |
STLN Hedge Fund Activity: Q1 2026 in Review
115 of the 8,141 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology Institute, Inc. Common Stock (STLN) for Q1 2026, worth a combined $119M — down 13% from $137M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of STLN and 25 opened new positions — a net loss of 1 holder — while 27 trimmed existing stakes and 51 added.
The largest buyer was Goldman Sachs, adding an estimated $2.4M. The largest seller was CenterBook Partners, cutting an estimated $4.48M.
- 115 institutional investors held Starling Oncology Institute, Inc. Common Stock (STLN) as of Q1 2026, down from 117 in Q4 2025.
- Funds reported $119M of Starling Oncology Institute, Inc. Common Stock stock for Q1 2026, down 13% quarter-over-quarter.
- 25 funds opened new Starling Oncology Institute, Inc. Common Stock positions in Q1 2026 and 26 closed out, a net change of -1 holder.
- The largest Starling Oncology Institute, Inc. Common Stock buyer in Q1 2026 was Goldman Sachs, an estimated $2.4M added.
- The largest Starling Oncology Institute, Inc. Common Stock seller in Q1 2026 was CenterBook Partners, an estimated $4.48M sold.
Based on aggregated 13F filings for Q1 2026.